PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represe ...

LOS ANGELES, April 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NASDAQ: VTRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the "Class Period"), are ...

PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team.Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Viatris A ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Viatris Inc. securities during the specified Class Period, indicating potential legal issues related to the company's disclosures and the impact of regulatory actions on its financials [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for securities purchased between August 8, 2024, and February 26, 2025, and investors may be entitled to compensation without upfront costs through a contingency fee arrangement [2][3]. - Investors wishing to serve as lead plaintiff must file a motion by June 3, 2025, and a lead plaintiff acts on behalf of other class members in directing the litigation [3]. Group 2: Allegations Against Viatris - The lawsuit claims that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that restricted the shipment of eleven products [5][6]. - Defendants allegedly downplayed the significance of the warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection timeline, remediation efforts, and the financial implications of the warning letter on Viatris' operations [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes its experience and success in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone, showcasing its capability to represent investors effectively [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Viatris between August 8, 2024 and February 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 13, 2025 (GLO ...

SAN DIEGO, April 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit.  Captioned Quinn v. Viatris Inc., No. 25-cv-00466 (W.D. Pa.), the Viatris class action lawsuit charges Viatris and certain of Viatris' top executives with violations of ...

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the cas ...

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud that negatively impacted investors between August 8, 2024, and February 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying it as a "minor headwind" [2]. - Following the announcement of disappointing financial results for Q4 and fiscal year 2024 on February 27, 2025, Viatris' stock price dropped from $11.24 to $9.53, a decline of approximately 15.21% in one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for allegedly providing misleading information regarding the FDA's warning letter related to its Indore, India facility, which impacted the company's operations [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Viatris securities between August 8, 2024, and February 26, 2025 [1]. - Investors have until June 3, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - The complaint claims that Viatris misrepresented the significance of the FDA's warning letter, downplaying it as a "minor headwind" for the company [2].

NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=141957&from=4CLASS PERIOD: August 8, 2024 to Februar ...